{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:42:38Z","timestamp":1791240158306,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008422","name":"Endocyte Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bmcl.2021.128091","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T10:50:00Z","timestamp":1620298200000},"page":"128091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Folate-targeted verrucarin A reduces the number of activated macrophages in a mouse model of acute peritonitis"],"prefix":"10.1016","volume":"42","author":[{"given":"Chelvam","family":"Venkatesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek D.","family":"Doorneweerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0619-2616","authenticated-orcid":false,"given":"Karson S.","family":"Putt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmcl.2021.128091_b0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaut.2009.11.018","article-title":"Defining and analyzing geoepidemiology and human autoimmunity","volume":"34","author":"Shapira","year":"2010","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128091_b0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The world incidence and prevalence of autoimmune diseases is increasing","volume":"3","author":"Lerner","year":"2015","journal-title":"Int J Celiac Dis"},{"issue":"10","key":"10.1016\/j.bmcl.2021.128091_b0015","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3389\/fimmu.2019.01140","article-title":"The role of monocytes and macrophages in autoimmune diseases: a comprehensive review","volume":"24","author":"Ma","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2021.128091_b0020","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K","article-title":"Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis","volume":"43","author":"Barrera","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bmcl.2021.128091_b0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.7150\/thno.9476","article-title":"Macrophages targeted theranostics as personalized nanomedicine strategies for inflammatory diseases","volume":"5","author":"Patel","year":"2015","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bmcl.2021.128091_b0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.57.7.408","article-title":"Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis","volume":"57","author":"Van Lent","year":"1998","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.bmcl.2021.128091_b0035","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/mp0700615","article-title":"Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus","volume":"4","author":"Varghese","year":"2007","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128091_b0040","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/ar1944","article-title":"Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis","volume":"8","author":"Paulos","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128091_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1912-0","article-title":"Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis","volume":"21","author":"Hu","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128091_b0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1189\/jlb.2AB0713-372R","article-title":"Folate receptor-\u03b2 constitutes a marker for human proinflammatory monocytes","volume":"96","author":"Shen","year":"2014","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.bmcl.2021.128091_b0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128091_b0060","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.addr.2004.02.003","article-title":"Folate receptor-targeted drugs for cancer and inflammatory diseases","volume":"56","author":"Low","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"issue":"19","key":"10.1016\/j.bmcl.2021.128091_b0065","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1021\/jm100509v","article-title":"Folate-targeted therapies for cancer","volume":"53","author":"Xia","year":"2010","journal-title":"J Med Chem"},{"issue":"4\u20136","key":"10.1016\/j.bmcl.2021.128091_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.drup.2014.10.002","article-title":"The folate receptor as a rational therapeutic target for personalized cancer treatment","volume":"17","author":"Assaraf","year":"2014","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.bmcl.2021.128091_b0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-94-007-2199-9_9","article-title":"Folate-linked drugs for the treatment of cancer and inflammatory diseases","volume":"56","author":"Yang","year":"2012","journal-title":"Subcell Biochem"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128091_b0080","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1007\/s13277-015-3706-6","article-title":"Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy","volume":"36","author":"Bahrami","year":"2015","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128091_b0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2119\/molmed.2015.00040","article-title":"Antiinflammatory activity of a novel folic acid targeted conjugate of the mTOR inhibitor everolimus","volume":"21","author":"Lu","year":"2015","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128091_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-021-02073-7","article-title":"Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis","volume":"18","author":"Elo","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128091_b0095","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.nano.2015.12.365","article-title":"Folate-targeted nanoparticle for rheumatoid arthritis therapy","volume":"12","author":"Nogueira","year":"2016","journal-title":"Nanomedicine"},{"issue":"9","key":"10.1016\/j.bmcl.2021.128091_b0100","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/art.30459","article-title":"Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis","volume":"63","author":"Thomas","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128091_b0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-018-0382-x","article-title":"Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis","volume":"16","author":"Duan","year":"2018","journal-title":"J Nanobiotechnol"},{"issue":"20","key":"10.1016\/j.bmcl.2021.128091_b0110","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.2217\/nnm-2017-0166","article-title":"Folate-conjugated liposomes target and deliver therapeutics to immune cells in a rat model of rheumatoid arthritis","volume":"12","author":"Poh","year":"2017","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"10.1016\/j.bmcl.2021.128091_b0115","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.nano.2018.01.009","article-title":"Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases","volume":"14","author":"Poh","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bmcl.2021.128091_b0120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/978-1-4684-4394-3_16","article-title":"Comparison of the in vivo and in vitro proliferation of monoblasts, promonocytes, and the macrophage cell line J774","volume":"155","author":"van Furth","year":"1982","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.bmcl.2021.128091_b0125","doi-asserted-by":"crossref","unstructured":"Fujimoto H. Mycotoxins | classification, occurrence and determination. Encyclopedia of Dairy Sciences. 2002;2079-2087. DOI:10.1016\/B0-12-227235-8\/00350-3.","DOI":"10.1016\/B0-12-227235-8\/00350-3"},{"issue":"8","key":"10.1016\/j.bmcl.2021.128091_b0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1593\/neo.12852","article-title":"Lack of a Functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A","volume":"14","author":"Woldemichael","year":"2012","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.bmcl.2021.128091_b0135","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1007\/s00204-017-2118-3","article-title":"Trichothecenes: immunomodulatory effects, mechanisms, and anti-cancer potential","volume":"91","author":"Wu","year":"2017","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128091_b0140","first-page":"57","article-title":"Antitumor activity of T-2 toxin-conjugated monoclonal antibody to murine thymoma","volume":"60","author":"Ohtani","year":"1990","journal-title":"Jpn J Exp Med"},{"issue":"4","key":"10.1016\/j.bmcl.2021.128091_b0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/nt.2620010402","article-title":"Anti-tumor activity of T-2 toxin-conjugated A7 monoclonal antibody (T-2-A7 MoAb) against human colon carcinoma","volume":"1","author":"Kojima","year":"1993","journal-title":"Nat Toxins"},{"issue":"11","key":"10.1016\/j.bmcl.2021.128091_b0150","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bbagen.2008.01.011","article-title":"Redox compartmentalization in eukaryotic cells","volume":"1780","author":"Go","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"37","key":"10.1016\/j.bmcl.2021.128091_b0155","doi-asserted-by":"crossref","first-page":"13872","DOI":"10.1073\/pnas.0601455103","article-title":"Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging","volume":"103","author":"Yang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.bmcl.2021.128091_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198943","article-title":"Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages","volume":"13","author":"Taciak","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2021.128091_b0165","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21003176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21003176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:40:02Z","timestamp":1760773202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21003176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":33,"alternative-id":["S0960894X21003176"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128091","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Folate-targeted verrucarin A reduces the number of activated macrophages in a mouse model of acute peritonitis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128091"}}